Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study
Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received.
We retrospectively collected 290 ALK rearranged advanced NSCLC diagnosed between 2011 and 2017 in 23 Italian institutions.
After a median follow-up of 26 months, PFS for crizotinib and a new generation ALKis were 9.4 [CI 95% 7.9–11.2] and 11.1 months [CI 95% 9.2–13.8], respectively, while TTF were 10.2 [CI 95% 8.5–12.6] and 11.9 months [CI 95% 9.7–17.4], respectively, being consistent across the different settings. The composed outcomes (the sum of PFS or TTF) in patients treated with crizotinib followed by a new generation ALKis were 27.8 months [CI 95% 24.3–33.7] in PFS and 30.4 months [CI 95% 24.7–34.9] in TTF. The median OS from the diagnosis of advanced disease was 39 months [CI 95% 31.8–54.5]. Patients receiving crizotinib followed by a new generation ALKis showed a higher median OS [57 months (CI 95% 42.0–73.8)] compared to those that did not receive crizotinib [38 months (CI 95% 18.6–NR)] and those who performed only crizotinib as target agent [15 months (CI 95% 11.3–34.0)] (P < 0.0001).
The sequential administration of crizotinib and a new generation ALKis provided a remarkable clinical benefit in this real-life population, being an interesting option to consider in selected patients.
KeywordsLung cancer ALK inhibitors Sequence
S. Novello, M. Di Maio, M. Tiseo, P. Graziano, D. Galetta, E. Bria, A. Rossi and G. Rossi contributed to the study conception and design. Material preparation, data collection and analysis were performed by E. Gobbini with the contribution of all other authors. The first draft of the manuscript was written by E. Gobbini and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
Dr. Gobbini reports personal fees from Astrazeneca, grants and personal fees from Bristol-Myers Squibb, personal fees from Roche, personal fees from Merck Sharpe and Dohme, outside the submitted work; Dr. Pilotto reports personal fees from Astrazeneca, personal fees from Eli-Lilly, personal fees from Bristol Mayers Squibb, personal fees from Boehringer Ingelheim, personal fees from Roche, personal fees from Merck Sharpe and Dohme, personal fees from Istituto Gentili, outside the submitted work; Dr. Scotti reports personal fees from Roche, personal fees from Pfizer, outside the submitted work; Dr. Rossi reports personal fees from Roche, outside the submitted work; Dr. Cappuzzo reports personal fees from Roche, personal fees from Astrazeneca, personal fees from Brystol Myers Squibb, personal fees from Takeda, personal fees from Pfizer, personal fees from Eli-Lilly, personal fees from Merck Sharpe and Dohme, outside the submitted work; Dr. Di Maio reports personal fees from Brystol Myers Squibb, personal fees from Merck Sharp and Dohme, personal fees from Roche, personal fees from Astrazeneca, personal fees from Janssen, personal fees from Takeda, personal fees from Pfizer, outside the submitted work; Dr. Tiseo reports personal fees from Astrazeneca, personal fees from Brystol Myers Squibb, personal fees from Merck Sharpe and Dohme, personal fees from Boehringer Ingelheim, from Takeda, outside the submitted work; Dr. Novello reports personal fees from Astrazeneca, personal fees from Boheringer Ingelheim, personal fees from Brystol Myers Squibb, personal fees from Celgene, personal fees from Eli-Lilly, personal fees from Abbvie, personal fees from Merck Sharpe and Dohme, personal fees from Takeda, personal fees from Pfizer, personal fees from Roche, outside the submitted work.
All procedures performed in this retrospective study involving human participants were in accordance with the ethical standards of the oncologic centers involved. Notably, this study (protocol n° 11/663) was approved by the central institutional review board of San Luigi Hospital in Orbassano (reference n° 91/2014) and the decision was transmitted to all the other oncologic centers involved.
Informed consent was obtained from all individual participants included in the study for retrieving data from hospital medical record systems. Anonymized data were thus collected at the San Luigi Hospital. This protocol did not modify patient’s clinical management.
- 1.Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13–7. https://doi.org/10.1097/JTO.0b013e31815e8b60.CrossRefPubMedGoogle Scholar
- 2.Barlesi F, Mazieres J, Merlio J-P, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier P-P, Lamy R, Beau-Faller M, Pujol J-L, Sabourin J-C, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria J-C, Zalcman G. Biomarkers France contributors, routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387:1415–26. https://doi.org/10.1016/S0140-6736(16)00004-0.CrossRefPubMedGoogle Scholar
- 3.Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390:29–39. https://doi.org/10.1016/S0140-6736(17)30565-2.CrossRefPubMedGoogle Scholar
- 4.Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, Ou S-HI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377:829–38. https://doi.org/10.1056/NEJMoa1704795.CrossRefPubMedGoogle Scholar
- 5.Camidge DR, Kim HR, Ahn M-J, Yang JC-H, Han J-Y, Lee J-S, Hochmair MJ, Li JY-C, Chang G-C, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim D-W, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus crizotinib in ALK-positive non–small-cell lung cancer. N Engl J Med. 2018;379:2027–39. https://doi.org/10.1056/NEJMoa1810171.CrossRefPubMedGoogle Scholar
- 6.Camidge DR PS, Shaw A, A. University of Colorado, L. Centre Hospitalier Universitaire Vaudois—CHUV, H.K. Chinese University of Hong Kong, A.A. University of Michigan, T. Sunnybrook Odette Cancer Centre, S.L. Northern Cancer Institute, M. European Institute of Oncology, M.C.O. Hospital №, M. 62 of Moscow Department of Health, S. Severence Hospital, G. Sun Yat-Sen University Cancer Center, G. Grenoble University Hospital, B. F. Hoffmann-La Roche Ltd., B. Massachusetts General Hospital, Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.(2018. https://meetinglibrary.asco.org/record/160811/abstract. Accessed 1 Mar 2019.Google Scholar
- 7.Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA. Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I/II, multicenter study. Clin Cancer Res. 2018;24:2771–9. https://doi.org/10.1158/1078-0432.CCR-17-2398.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin C-C, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini J-F, Chen J, Peltz G, Thurm H, Ou S-HI, Shaw AT. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654–67. https://doi.org/10.1016/S1470-2045(18)30649-1.CrossRefPubMedGoogle Scholar
- 9.NCT02097810_Study of Oral RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations, (n.d.).Google Scholar
- 10.NCT03093116_A Study of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1–3 Rearrangements, (n.d.).Google Scholar
- 11.Novello S, Mazières J, Oh I-J, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29:1409–16. https://doi.org/10.1093/annonc/mdy121.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:874–86. https://doi.org/10.1016/S1470-2045(17)30339-X.CrossRefPubMedGoogle Scholar
- 13.Kim D-W, Tiseo M, Ahn M-J, Reckamp KL, Hansen KH, Kim S-W, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35:2490–8. https://doi.org/10.1200/JCO.2016.71.5904.CrossRefPubMedGoogle Scholar
- 14.Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L. International Association for the Study of Lung Cancer International Staging Committee, Participating Institutions, the IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14. https://doi.org/10.1097/JTO.0b013e31812f3c1a.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou S-HI. Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2017.76.2294.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–33. https://doi.org/10.1158/2159-8290.CD-16-0596.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Solomon BJ, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non–small-cell lung cancer. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2017.77.4794.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Felip E, Nishio M, Orlov S, Park K, Yu C-J, Tsai C-M, Cobo M, McKeage M, Su W-C, Mok T, Scagliotti G, Spiegel M, Passos V, Chen Z, Shaw AT, Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3), in: n.d. https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Overall-survival-results-of-ceritinib-in-ALKi-naive-patients-with-ALK-rearranged-NSCLC-ASCEND-3. Accessed 18 Mar 2019.
- 21.Reynolds C, Masters ET, Black-Shinn J, Boyd M, Mardekian J, Espirito JL, Chioda M. Real-world use and outcomes of ALK-positive crizotinib-treated metastatic NSCLC in US community oncology practices: a retrospective observational study. J Clin Med. 2018;7:1–2. https://doi.org/10.3390/jcm7060129.CrossRefGoogle Scholar
- 23.Soria J-C, Tan DSW, Chiari R, Wu Y-L, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu C-J, Hochmair M, Cortot AB, Tsai C-M, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389:917–29. https://doi.org/10.1016/S0140-6736(17)30123-X.CrossRefPubMedGoogle Scholar
- 24.Gobbini E, Galetta D, Tiseo M, Graziano P, Rossi A, Bria E, Di Maio M, Rossi G, Gregorc V, Riccardi F, Scotti V, Ceribelli A, Buffoni L, Delmonte A, Franchina T, Migliorino MR, Cortinovis D, Pisconti S, Bordi P, Catino A, Maiello E, Arizio F, Novello S, et al. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: an observational prospective study. Lung Cancer Amst Neth. 2017;111:30–7. https://doi.org/10.1016/j.lungcan.2017.06.009.CrossRefGoogle Scholar